Global InformationPrasterone information
 | |
 | |
| Clinical data | |
|---|---|
| Trade names | Intrarosa, others |
| Other names | EL-10; GL-701; KYH-3102; Androst-5-en-3β-ol-17-one; 3β-Hydroxyandrost-5-en-17-one; 5,6-Didehydroepiandrosterone;[1] Dehydroisoepiandrosterone[2] |
| AHFS/Drugs.com | Monograph |
| MedlinePlus | a617012 |
| License data |
|
| Pregnancy category |
|
| Routes of administration | By mouth, vaginal (rectal), intramuscular (as prasterone enanthate), injection (as prasterone sodium sulfate) |
| Drug class | Androgen; Anabolic steroid; Estrogen; Neurosteroid |
| ATC code |
|
| Legal status | |
| Legal status |
|
| Pharmacokinetic data | |
| Bioavailability | 50%[9] |
| Metabolism | Liver[9] |
| Metabolites | • Androsterone[9] • Etiocholanolone[9] • DHEA sulfate[9] • Androstenedione[9] • Androstenediol[9] • Testosterone[9] • Dihydrotestosterone • Androstanediol[9] • Estrone • Estradiol |
| Elimination half-life | DHEA: 25 minutes[10] DHEA-S: 11 hours[10] |
| Excretion | Urine |
| Identifiers | |
IUPAC name
| |
| CAS Number |
|
| PubChem CID |
|
| IUPHAR/BPS |
|
| DrugBank |
|
| ChemSpider |
|
| UNII |
|
| KEGG |
|
| ChEBI |
|
| ChEMBL |
|
| Chemical and physical data | |
| Formula | C19H28O2 |
| Molar mass | 288.431 g·mol−1 |
| 3D model (JSmol) |
|
| Melting point | 148.5 °C (299.3 °F) |
SMILES
| |
InChI
| |
| (verify) | |
Prasterone, also known as dehydroepiandrosterone (DHEA) and sold under the brand name Intrarosa among others, is a medication as well as over-the-counter dietary supplement which is used to correct DHEA deficiency due to adrenal insufficiency or old age, as a component of menopausal hormone therapy, to treat painful sexual intercourse due to vaginal atrophy, and to prepare the cervix for childbirth, among other uses.[9][11] It is taken by mouth, by application to the skin, in through the vagina, or by injection into muscle.[11]
Side effects of prasterone in women include symptoms of masculinization like oily skin, acne, increased hair growth, voice changes, and increased sexual desire, headaches, insomnia, and others.[9][11] The compound is a naturally occurring prohormone of androgens and estrogens and hence is an agonist of the androgen and estrogen receptors, the respective biological targets of androgens like testosterone and estrogens like estradiol.[9][12] Prasterone also has a variety of activities of its own, including neurosteroid and other activities.[12]
DHEA, the active ingredient of prasterone, was discovered in 1934.[9][11] An association between DHEA levels and aging was first reported in 1965.[9][11] The compound started being used as a medication in the late 1970s and as a supplement in the early 1980s.[9][11] The marketing of prasterone over-the-counter as a supplement is allowed in the United States but is banned in many other countries.[9]
- ^ Devillers J (27 April 2009). Endocrine Disruption Modeling. CRC Press. pp. 339–. ISBN 978-1-4200-7636-3.
- ^ Cite error: The named reference
Elks-2014was invoked but never defined (see the help page). - ^ "Intrarosa". Therapeutic Goods Administration (TGA). 26 June 2023. Retrieved 10 September 2023.
- ^ "Intrarosa (Theramex Australia Pty Ltd)". Therapeutic Goods Administration (TGA). 28 July 2023. Retrieved 10 September 2023.
- ^ https://www.tga.gov.au/resources/auspar/auspar-intrarosa
- ^ Anvisa (31 March 2023). "RDC Nº 784 - Listas de Substâncias Entorpecentes, Psicotrópicas, Precursoras e Outras sob Controle Especial" [Collegiate Board Resolution No. 784 - Lists of Narcotic, Psychotropic, Precursor, and Other Substances under Special Control] (in Brazilian Portuguese). Diário Oficial da União (published 4 April 2023). Archived from the original on 3 August 2023. Retrieved 15 August 2023.
- ^ "Summary Basis of Decision (SBD) for Intrarosa". Health Canada. 23 October 2014. Archived from the original on 31 May 2022. Retrieved 29 May 2022.
- ^ "Intrarosa- prasterone insert". DailyMed. 22 November 2021. Archived from the original on 31 May 2022. Retrieved 29 May 2022.
- ^ a b c d e f g h i j k l m n o p Cupp MJ, Tracy TS (10 December 2002). Dietary Supplements: Toxicology and Clinical Pharmacology. Springer Science & Business Media. pp. 123–147. ISBN 978-1-59259-303-3. Archived from the original on 14 January 2023. Retrieved 4 March 2018.
- ^ a b Oddens BJ, Vermeulen A (15 November 1996). Androgens and the Aging Male. CRC Press. pp. 5–. ISBN 978-1-85070-763-9. Archived from the original on 14 January 2023. Retrieved 17 July 2017.
- ^ a b c d e f Rutkowski K, Sowa P, Rutkowska-Talipska J, Kuryliszyn-Moskal A, Rutkowski R (July 2014). "Dehydroepiandrosterone (DHEA): hypes and hopes". Drugs. 74 (11): 1195–1207. doi:10.1007/s40265-014-0259-8. PMID 25022952. S2CID 26554413.
- ^ a b Prough RA, Clark BJ, Klinge CM (April 2016). "Novel mechanisms for DHEA action". Journal of Molecular Endocrinology. 56 (3): R139–R155. doi:10.1530/JME-16-0013. PMID 26908835.